These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 25772366)
1. Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. Chen YH; McGowan LD; Cimino PJ; Dahiya S; Leonard JR; Lee DY; Gutmann DH Cell Rep; 2015 Mar; 10(11):1899-912. PubMed ID: 25772366 [TBL] [Abstract][Full Text] [Related]
2. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells. Kim RK; Kim MJ; Yoon CH; Lim EJ; Yoo KC; Lee GH; Kim YH; Kim H; Jin YB; Lee YJ; Cho CG; Oh YS; Gye MC; Suh Y; Lee SJ Mol Pharmacol; 2012 Sep; 82(3):400-7. PubMed ID: 22648970 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of CD133 promotes drug resistance in C6 glioma cells. Angelastro JM; Lamé MW Mol Cancer Res; 2010 Aug; 8(8):1105-15. PubMed ID: 20663862 [TBL] [Abstract][Full Text] [Related]
4. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381 [TBL] [Abstract][Full Text] [Related]
5. Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia. Alakhova DY; Zhao Y; Li S; Kabanov AV PLoS One; 2013; 8(8):e72238. PubMed ID: 23977261 [TBL] [Abstract][Full Text] [Related]
6. Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma. Yang JP; Liu Y; Zhong W; Yu D; Wen LJ; Jin CS Chin Med J (Engl); 2011 Apr; 124(7):1055-60. PubMed ID: 21542968 [TBL] [Abstract][Full Text] [Related]
7. Enhanced invasion in vitro and the distribution patterns in vivo of CD133+ glioma stem cells. Yu SP; Yang XJ; Zhang B; Ming HL; Chen C; Ren BC; Liu ZF; Liu B Chin Med J (Engl); 2011 Sep; 124(17):2599-604. PubMed ID: 22040410 [TBL] [Abstract][Full Text] [Related]
8. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. Ping YF; Yao XH; Jiang JY; Zhao LT; Yu SC; Jiang T; Lin MC; Chen JH; Wang B; Zhang R; Cui YH; Qian C; Wang Jm; Bian XW J Pathol; 2011 Jul; 224(3):344-54. PubMed ID: 21618540 [TBL] [Abstract][Full Text] [Related]
9. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Dahlrot RH Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629 [TBL] [Abstract][Full Text] [Related]
10. CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells. Barrantes-Freer A; Renovanz M; Eich M; Braukmann A; Sprang B; Spirin P; Pardo LA; Giese A; Kim EL PLoS One; 2015; 10(6):e0130519. PubMed ID: 26086074 [TBL] [Abstract][Full Text] [Related]
11. Study on the proliferation and drug-resistance of human brain tumor stem-like cells. Qin K; Jiang X; Zou Y; Wang J; Qin L; Zeng Y Cell Mol Neurobiol; 2010 Aug; 30(6):955-60. PubMed ID: 20526804 [TBL] [Abstract][Full Text] [Related]
12. [Chemoresistance of CD133(+) tumor stem cells from human brain glioma]. Bi CL; Fang JS; Chen FH; Wang YJ; Wu J Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Aug; 32(4):568-73. PubMed ID: 17767043 [TBL] [Abstract][Full Text] [Related]
13. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro. Huang Q; Zhang QB; Dong J; Wu YY; Shen YT; Zhao YD; Zhu YD; Diao Y; Wang AD; Lan Q BMC Cancer; 2008 Oct; 8():304. PubMed ID: 18940013 [TBL] [Abstract][Full Text] [Related]
14. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Bao S; Wu Q; McLendon RE; Hao Y; Shi Q; Hjelmeland AB; Dewhirst MW; Bigner DD; Rich JN Nature; 2006 Dec; 444(7120):756-60. PubMed ID: 17051156 [TBL] [Abstract][Full Text] [Related]
15. ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. Jin Y; Bin ZQ; Qiang H; Liang C; Hua C; Jun D; Dong WA; Qing L J Cancer Res Clin Oncol; 2009 Oct; 135(10):1369-76. PubMed ID: 19340456 [TBL] [Abstract][Full Text] [Related]
16. Limits of CD133 as a marker of glioma self-renewing cells. Clément V; Dutoit V; Marino D; Dietrich PY; Radovanovic I Int J Cancer; 2009 Jul; 125(1):244-8. PubMed ID: 19350631 [TBL] [Abstract][Full Text] [Related]
17. Enhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions. Fang KM; Lin TC; Chan TC; Ma SZ; Tzou BC; Chang WR; Liu JJ; Chiou SH; Yang CS; Tzeng SF Glia; 2013 Sep; 61(9):1402-17. PubMed ID: 23832679 [TBL] [Abstract][Full Text] [Related]
18. Expression of multidrug resistance genes in normal and cancer stem cells. Shervington A; Lu C Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776 [TBL] [Abstract][Full Text] [Related]
19. Characterization of glioma stem-like cells from human glioblastomas. Yamamuro S; Okamoto Y; Sano E; Ochiai Y; Ogino A; Ohta T; Hara H; Ueda T; Nakayama T; Yoshino A; Katayama Y Int J Oncol; 2015 Jul; 47(1):91-6. PubMed ID: 25955568 [TBL] [Abstract][Full Text] [Related]
20. CXCR4-positive subset of glioma is enriched for cancer stem cells. Zheng X; Xie Q; Li S; Zhang W Oncol Res; 2011; 19(12):555-61. PubMed ID: 22812188 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]